Valeant¤U©P¤½¥¬¥½©u«×·~ÁZ
¡i©ú³ø±M°T¡jValeant Pharmaceutical International(¥N¸¹VRX)«Å¥¬¡A¨M©w¤U©P¤Gµoªí²Ä¥|©u«×·~ÁZ¤Î«e´º¹w´ú¡F¸Ó¶°¹Îìp¹º¦b2¤ë29¤é¤½¥¬¥½©u«×·~ÁZ¡A¦ý¥Ñ©ó¶°¹Î¦æ¬FÁ`µôMichael Pearsonè©ó2¤ë28¤é¯f°²«á´_¤u¡A¬G¶°¹Î¨M©w±À©µ¤½¥¬¥½©u«×·~ÁZªº¤é´Á¡A¬Q¤Ñp¹º3¤ë15¤é¥¿¦¡¤½¥¬·~ÁZ¡C
Pearson¬Q¤Ñªí¥Ü¡A¤w¦^¨ì±^¦ì¤W¡A²{¥¿¼f¬d·~°È¡A¤U©P±N»PªÑªF¤À¨É³Ì·s·~°Èª¬úG¡C
Valeantªº³Ì·s©u«×·~ÁZ±N¥i¤Ï¬M¬ü°êÃҺʷ|ªº½Õ¬d©Ò¤ÞPªº¼vÅT¤Î¨ãÅé²Ó¸`¡F¬ü°êÃҺʷ|n¨DValeant»P¤À¾P°ÓPhilidor Rx Services LLCÂ_µ´¥ô¦óÃö«Y¡C
¾Ú®ø®§¤H¤h«ü¥X¡AValeant¦V¬ü°êÃҺʷ|§e¥æªº¤å¥ó¡A·í¤¤¥]¬A°]°È³ø§i¤Î¨ä¥L¼Æ¾Ú¡A§¡¥O¬ü°êÃҺʷ|·P¨ìº¡·N¤Î²Å¦Xn¨D¡C
¥t¥~¡APearson¥ç¨ü¨ì°]°È«H®§©ÜÅS¤Î°Ó·~ºD¨Ò§åµû¤Î½èºÃ¡FValeant¤W©P¥ç«Å¥¬¡At³d¬ü°ê¥Ö½§¯f²£«~·~°Èªº°ª¼hDeb Jorn¡A¤w¦]Ó¤H²z¥Ñ¦ÓÂ÷¾¡C
ValeantªÑ»ù¥Ñ¥h¦~®L©u°ª¦ì¦Ü¤µ¤w¤U¶^¥|¤À¤T¡A¥Dn¬O¨ü¬ü°êÃҺʷ|½Õ¬d®ø®§©Ò¼vÅT¡FªÑ»ù¬Q¤Ñ¦¬³ø87.15¤¸¡A¤W¤É5.51¤¸¡A©Î6.75¢H¡F¦b¯Ã¬ù¦¬³ø65.66¬ü¤¸¡A¤W¤É4.35¬ü¤¸¡A©Î7.1¢H¡C